Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Novel and Combination Therapies for Hepatitis C Virus - p. 6 7. The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States - p. 7 8. Hepatitis C Viral Kinetics - p. 13 9. Hepatitis C Virus Viral Assays in the Direct-Acting Antiviral Era - p. 21 10. Telaprevir for Chronic Hepatitis C Virus Infection - p. 29 11. Boceprevir and Treatment of Chronic Hepatitis C - p. 38 12. Management of the Transplant Recipient with Chronic Hepatitis C - p. 44 13. Update on Combinations of DAAs With and Without Pegylated-Interferon and Ribavirin - p. 53 14. Nucleoside/Nucleotide Analogue Polymerase Inhibitors in Development - p. 58 15. HCV NS5A Inhibitors in Development - p. 62 16. Non-nucleoside Analogue Polymerase Inhibitors in Development - p. 67 17. Cyclophilin Inhibitors for Hepatitis C Therapy - p. 70 18. Index - p. 75
No hay muestra disponible
No hay ficha técnica disponible
Dr. Pockros has created a clinically focused issue based on the CONO 2012 meeting, whereby he was able to have those presenters write articles for his issue. Therefore, the content for HCV in this issue reflects the most current knowledge. The issue is focused on basic/current information, current therapy and special populations, triple and quad combination therapies in development, and an article on second generation protease inhibitors. The reader can expect that this issue will provide thorough clinical reviews on the most current therapeutic options for HCV.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Forthcoming Issues - p. 5 6. Novel and Combination Therapies for Hepatitis C Virus - p. 6 7. The Epidemiology of Chronic Hepatitis C and One-Time Hepatitis C Virus Testing of Persons Born During 1945 to 1965 in the United States - p. 7 8. Hepatitis C Viral Kinetics - p. 13 9. Hepatitis C Virus Viral Assays in the Direct-Acting Antiviral Era - p. 21 10. Telaprevir for Chronic Hepatitis C Virus Infection - p. 29 11. Boceprevir and Treatment of Chronic Hepatitis C - p. 38 12. Management of the Transplant Recipient with Chronic Hepatitis C - p. 44 13. Update on Combinations of DAAs With and Without Pegylated-Interferon and Ribavirin - p. 53 14. Nucleoside/Nucleotide Analogue Polymerase Inhibitors in Development - p. 58 15. HCV NS5A Inhibitors in Development - p. 62 16. Non-nucleoside Analogue Polymerase Inhibitors in Development - p. 67 17. Cyclophilin Inhibitors for Hepatitis C Therapy - p. 70 18. Index - p. 75
No hay muestra disponible
No hay ficha técnica disponible
